Nektar Therapeutics launches Inheris Biopharma

Nektar Therapeutics launches Inheris Biopharma

Source: 
Pharmaceutical Business Review
snippet: 

Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company.